/
Since our incorporation in January 2012, our operations to date have included organizing and staffing our company, business planning, raising capital, developing our compounds, engaging in other discovery and preclinical activities, the commercial launches of AUVELITY and SUNOSI, and preparatory activities for the launch of SYMBRAVO. Subsequent to our IPO, we financed our operations primarily t…
The business is unprofitable at the operating level (-26.12% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 65.5% YoY with margins expanding 46.6pp.
Negative free cash flow of -$94M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$708M
▲ +65.5% YoY
Net Income (TTM)
-$188M
▲ +36.2% YoY
Op. Margin
-24.45%
▲ +46.6pp YoY
ROIC
-47.02%
▲ +23.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$71M
▲ +27.0% YoY
Op. Cash Flow (TTM)
-$71M
▲ +27.3% YoY
Net Debt
-$85M
Net Cash Position
Cash & Equiv.
$305M
Continue Research